HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

Core Viewpoint - HUTCHMED is withdrawing TAZVERIK from the Chinese market following Ipsen's voluntary withdrawal in the US due to safety concerns related to secondary hematologic malignancies observed in clinical trials [1][2][3] Group 1: Product Withdrawal and Clinical Trials - Ipsen has informed HUTCHMED of the immediate withdrawal of TAZVERIK, affecting both follicular lymphoma and epithelioid sarcoma treatments [2][3] - HUTCHMED has initiated a market withdrawal and product recall in China, Hong Kong, and Macau, and is discontinuing all active clinical trials involving tazemetostat [1][4] - Existing patients are advised to consult their healthcare providers regarding alternative treatment options [1] Group 2: Regulatory and Safety Measures - HUTCHMED has promptly notified healthcare professionals and regulatory authorities, including the China National Medical Products Administration, about the withdrawal [4] - The company has suspended all sales and shipments of TAZVERIK and instructed healthcare institutions to cease prescribing it [4] Group 3: Financial Impact - The withdrawal of TAZVERIK is not expected to impact HUTCHMED's financial guidance, with reported sales of TAZVERIK at US$2.5 million in 2025 [6] Group 4: Background on TAZVERIK - TAZVERIK is a first-in-class methyltransferase inhibitor of EZH2, initially approved by the US FDA in 2020 under the accelerated approval program [5] - The drug received conditional approval from the NMPA for treating follicular lymphoma as an imported drug, subject to ongoing regulatory obligations [5] Group 5: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7]